Skip to content

Quantifying Muscle Tone in Patients With Brain Injury - a Feasibility Study

Quantifying Muscle Tone in Patients With Brain Injury - a Feasibility Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04207632
Enrollment
5
Registered
2019-12-23
Start date
2020-04-01
Completion date
2021-04-01
Last updated
2020-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment Outcome, Muscle Dystonia, Spasticity, Muscle, Muscle Tightness, Acquired Brain Injury, Muscle Tone Abnormalities

Keywords

Shear wave elastography, Portable spasticity assessment device, Feasibility, Outcome measure, Reliability, Validity, Clinimetrics

Brief summary

This project will determine the feasibility and validity of measuring elbow muscle flexor stiffness in a population of patients with sub-acute severe acquired brain injury using two measurement methods, the portable spasticity assessment device (PSAD) (Movotec, Charlottenlund, Denmark) and an ultrasound measurement called shear wave sonoelastography (SWE).

Detailed description

The purpose of this study is to investigate the feasibility and validity of measuring hypertonia in the elbow flexors of patients with severe acquired brain injury in their sub-acute rehabilitation and collect data to determine the necessary size for a definitive study to determine the clinimetrics of the test methods. The long-term goal is to establish a valid and clinically feasible method for physiotherapists to quantify muscle tone in patients with neurological disorders. The study hypotheses are: 1. SWE, PSAD and Modified Ashworth Scale (MAS) measurements can be obtained for elbow flexion hypertonia in all patients (no missing data due to test procedure), 2. SWE and PSAD have a moderate to good intra-day intra-tester reliability (ICC two-way mixed effects model with absolute agreement. ICC\>0.5, Bland Altman) 3. Passive muscle stiffness measured using the PSAD and SWE have a fair concurrent validity with MAS (Spearmans correlation \>0.3) 4. SWE and PSAD are responsive in measuring a reduction of the effect of routine clinical treatment of the hypertonic muscles with botulinum toxin type A (BTX-A) (paired T-test or Wilcoxon test, p\>0.05)

Interventions

Ultrasound-guided BoNT-A injection in biceps brachii or brachialis

Sponsors

Elsass Foundation
CollaboratorOTHER
Hvidovre University Hospital
CollaboratorOTHER
Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 99 Years

Inclusion criteria

The project will include five patients admitted to the clinic for highly specialised neurorehabilitation/TBI. Inclusion criteria for the patients are that they: 1. Fulfil the normal clinical requirements for treatment with BTX-A in at least one of their elbow flexors, (have increased stiffness in at least one of their elbow flexors, MAS greater than 0), 2. Have given the normal informed consent to routine clinical treatment with BTX-A, 3. Have given written informed consent or that proxy consent has been obtained, to participate in the study

Exclusion criteria

for patients are that they: 1. Are unable to cooperate with the measurements due to uncontrolled non-voluntary movements 2. Cannot be positioned safely or comfortably for the measurements.

Design outcomes

Primary

MeasureTime frameDescription
Change in resistance to elbow extension measured using the portable spasticity assessment device (PSAD)Twice at baseline and 4 weeks post BoNT-A injectionThe patient will be measured bilaterally using a PSAD.The PSAD utilises a load cell, gyroscopes and accelerometers and electromyography (EMG) and can measure full passive joint torque and joint angle together with corresponding muscle activity. A reduced passive moment in Nm when moving the joint indicates a reduced tissue stiffness.
Change in muscle stiffness in the treated muscle(s) measured using the shear wave elastography (SWE)Twice at baseline and 4 weeks post BoNT-A injectionThe patient will be scanned using an ultrasound scanner with shear wave elastography in the treated muscle and the contralateral equivalent. A reduced speed of propgation of the shear waves in m per second indicates a reduced stiffness/tone in the muscle.

Secondary

MeasureTime frameDescription
Muscle tone measured using modified ashworth scaleBaseline and 4 weeks post BoNT-A injectionFollowing standard clinical tone assessment procedure. The scale is from 0 to 4, where a lower value is indicative of a more normal muscle tone.
Passive range of motionBaseline and 4 weeks post BoNT-A injectionPassive range of motion in flexion and extension of the elbow joint will be measured. A normal range of motion is associated with normal muscle tone. A reduced range of motion can indicate increased muscle tone.

Countries

Denmark

Contacts

Primary ContactDerek J Curtis, phd
derek.john.curtis@regionh.dk004538626683
Backup ContactIngrid Poulsen, phd
ingrid.poulsen@regionh.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026